Patents Examined by Jean Cornet
  • 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
    Patent number: 9284250
    Abstract: The present invention concerns a pharmaceutical compound having the Formula (1): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a cognitive, neurodegenerative or neuronal disorder or disease such as the Alzheimer Disease, a pharmaceutical composition and a method of preparing a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: March 15, 2016
    Assignee: CESA ALLIANCE S.A.
    Inventor: Reiner Van Tilborg
  • Rapidly dissolving pharmaceutical composition
    Patent number: 9284341
    Abstract: The present invention relates to a pharmaceutical dosage form which may comprise carbamoyl glycinated chitosan, and particularly it relates to a pharmaceutical dosage form comprising the novel polymer in a lyophilized polymeric wafer form which shows rapid disintegration and dissolution characteristics in use.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: March 15, 2016
    Assignee: UNIVERSITY OF THE WITWATERSRAND
    Inventors: Pradeep Kumar, Viness Pillay, Yahya Essop Choonara
  • Heterocyclic tyrosine kinase inhibitors
    Patent number: 9273028
    Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: March 1, 2016
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Brian T. Hopkins, Daniel Scott, Patrick Conlon, Tracy J. Jenkins, Noel Powell, Bing Guan, Julio H. Cuervo, Deping Wang, Art Taveras
  • Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
    Patent number: 9273064
    Abstract: Compounds of the general formula I wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—; R3 is —CHF2, —CF3, —OCHF2, —OCF3, —SCHF2 or —SCF3; X is a bond, —CH2—, or —NH—; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; and R4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy; or pharmaceutically acceptable salts, hydrates or solvates thereof, have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: March 1, 2016
    Assignee: LEO PHARMA A/S
    Inventor: Simon Feldbaek Nielsen
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9266877
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: February 23, 2016
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9260431
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 16, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Jayhong A. Chong
  • Infusion and injection solution of Levodopa
    Patent number: 9248113
    Abstract: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: February 2, 2016
    Assignee: Dizlin Medical Design AB
    Inventor: Nil Dizdar Segrell
  • Tau imaging probe
    Patent number: 9249101
    Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: February 2, 2016
    Assignee: CLINO LTD.
    Inventors: Yukitsuka Kudo, Shozo Furumoto, Nobuyuki Okamura
  • Methods of treating or preventing neuropathic pain
    Patent number: 9226924
    Abstract: A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel ?2? ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent used in the method includes as effective ingredients a cyclohexane derivative or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel ?2? ligand.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 5, 2016
    Assignee: Toray Industries, Inc.
    Inventors: Naoki Izumimoto, Hidenori Mochizuki
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9227963
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers
  • Heterocyclic compounds for the treatment of stress-related conditions
    Patent number: 9206173
    Abstract: The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: December 8, 2015
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akira Takahashi, Masaki Suzuki, Yuichi Nakamura, Yohji Sakurai
  • Substituted pyridine compound
    Patent number: 9187450
    Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: November 17, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Nakamura, Hidenori Namiki, Naoki Terasaka, Akiko Shima, Masahiko Hagihara, Noriaki Iwase, Katsunori Takata, Osamu Kikuchi, Kazunari Tsuboike, Hiroyuki Setoguchi, Kenji Yoneda, Hidetoshi Sunamoto, Koji Ito
  • Protein kinase inhibitors
    Patent number: 9174996
    Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: November 3, 2015
    Assignee: Astar Biotech LLC
    Inventors: Chunrong Yu, Haihong Huang, Dongfeng Zhang, Peng Li
  • Carbon monoxide releasing molecules and uses thereof
    Patent number: 9163044
    Abstract: Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I): and esters, amides, salts, solvates and hydrates thereof; wherein R1 and R2 are as described herein. Also provided are pharmaceutical compositions comprising these compounds, methods of their preparation, and their use in the treatment of liver disease and inflammation.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: October 20, 2015
    Assignee: Alfama, Inc.
    Inventors: Walter Anton Blättler, Carlos J. R. C. Romão, Sandra Sofia Pereira Rodrigues, Lukas Adrian Kromer, Leo Edmond Otterbein, David John Gallo
  • Compositions and methods for treatment and prevention of hyperuricemia related health consequences
    Patent number: 9155740
    Abstract: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: October 13, 2015
    Inventors: Richard J. Johnson, Takahiko Nakagawa
  • Pharmaceutical composition
    Patent number: 9149532
    Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: October 6, 2015
    Assignee: Daiichi Sanykyo Company, Limited
    Inventors: Masazumi Kojima, Yoshio Kuno, Hiroaki Nakagami, Shinji Sagasaki, Koichi Ishidoh, Gaku Sekiguchi
  • Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives
    Patent number: 9149467
    Abstract: The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: October 6, 2015
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Bing Li, Yunde Xie, Xinbo Zhou
  • Methods for treatment of diseases
    Patent number: 9149483
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 6, 2015
    Assignee: GALERA LABS, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Heteroaryls and uses thereof
    Patent number: 9139589
    Abstract: This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: September 22, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Masaaki Hirose, Steven P. Langston, Hirotake Mizutani, Stepan Vyskocil
  • Treating critically ill patients with intravenous ibuprofen
    Patent number: 9138404
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 22, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Amy Dix Rock